Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration

P William ConradDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA

David N ZacksDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA

Mark W JohnsonDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USACorrespondence[email protected]

Pages 727-733 | Published online: 05 Dec 2008

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

AielloLPPierceEAFoleyED1995Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteinsProc Natl Acad Sci USA9210457617479819
PubMed Web of Science ®Google Scholar
AisenbreySZiemssenFVolkerM2007Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degenerationGraefe’s Arch Clin Exp Ophthalmol2459418
PubMed Web of Science ®Google Scholar
AveryRLPieramiciDJRabenaMD2006Intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationOphthalmology1133637216458968
PubMed Web of Science ®Google Scholar
BashshurZFBazarbachiASchakalA2006Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degenerationAm J Ophthalmol1421916815245
PubMed Web of Science ®Google Scholar
BrownDMKaiserPKMichelsM2006Ranibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med35514324417021319
PubMed Web of Science ®Google Scholar
CostaRAJorgeRCalucciD2006Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase 1 dose-escalation studyInvest Ophthalmol Vis Sci4745697817003454
PubMed Web of Science ®Google Scholar
FungAELalwaniGARosenfeldPJ2007An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol1435668317386270
PubMed Web of Science ®Google Scholar
GragoudasESAdamisAPCunninghamETJr2004Pegaptanib for neovascular age-related macular degenerationN Engl J Med35128051615625332
PubMed Web of Science ®Google Scholar
HeierJSAntoszykANPavanPR2006Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose studyOphthalmology1136334216483659
PubMed Web of Science ®Google Scholar
KvantaAAlgverePVBerglinL1996Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factorInvest Ophthalmol Vis Sci371929348759365
PubMed Web of Science ®Google Scholar
LopezPFSippyBDLambertHM1996Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranesInvest Ophthalmol Vis Sci37855868
Web of Science ®Google Scholar
MatsuokaMOgataNOtsujiT2004Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathyBr J Ophthalmol888091515148217
PubMed Web of Science ®Google Scholar
MichelsSRosenfeldPJPuliafitoCA2005Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical studyOphthalmology11210354715936441
PubMed Web of Science ®Google Scholar
MordentiJCuthbertsonRAFerraraN1999Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administrationToxicol Pathol275364410528633
PubMed Web of Science ®Google Scholar
RakicJMLambertVDevyL2003Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci4431869312824270
PubMed Web of Science ®Google Scholar
RichRMRosenfeldPJPuliafitoCA2006Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationRetina2649551116770255
PubMed Web of Science ®Google Scholar
RosenfeldPJMoshfeghiAAPuliafitoCA2005Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degenerationOphthalmic Surg Lasers Imaging36331516156152
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJS2006aRanibizumab for neovascular age-related macular degenerationN Engl J Med35514193117021318
PubMed Web of Science ®Google Scholar
RosenfeldPJHeierJSHantsbargerG2006bTolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degenerationOphthalmology1136233216581423
PubMed Web of Science ®Google Scholar
RosenfeldPJRichRMLalwaniGA2006cRanibizumab: Phase III clinical trial resultsOphthalmol Clin North Am193617216935211
PubMedGoogle Scholar
SaddeSRWuZWalshAC2006Errors in retinal thickness measurements obtained by optical coherence tomographyOphthalmology1132859316406542
PubMed Web of Science ®Google Scholar
SpaideRFLaudKFineHF2006Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degenerationRetina263839016603955
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date